Person:
ERKAN ÖZMARASALI, BUKET

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

ERKAN ÖZMARASALI

First Name

BUKET

Name

Filters

20222
Reset filters

Settings

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Platin-based chemotherapy does not improve survival in patients with non-metastatic resected typical carcinoid tumors
    (Spandidos Publ Ltd, 2022-10-01) Şahin, Ahmet Bilgehan; Melek, Hüseyin; Ocak, Birol; Oyucu Orhan, Sibel; Erkan, Buket; Caner, Burcu; Deligönül, Adem; Çubukcu, Erdem; Bayram, Ahmet Sami; Akyıldız, Elif Ülker; Evrensel, Türkkan; ŞAHİN, AHMET BİLGEHAN; MELEK, HÜSEYİN; OCAK, BİROL; OYUCU ORHAN, SİBEL; ERKAN ÖZMARASALI, BUKET; CANER, BURCU; DELİGÖNÜL, ADEM; ÇUBUKÇU, ERDEM; BAYRAM, AHMET SAMİ; AKYILDIZ, ELİF ÜLKER; EVRENSEL, TÜRKKAN; Tıp Fakültesi; Tıbbi Onkoloji Ana Bilim Dalı; 0000-0002-7846-0870; 0000-0003-0684-0900; 0000-0003-1822-8153; 0000-0001-8217-3471; 0000-0003-1591-3323; AAM-4927-2020; AAI-5039-2021; AEC-2238-2022; AAJ-8314-2021; CPN-8681-2022; HJH-6371-2023; ESM-4544-2022; ETP-1691-2022; ABB-7580-2020; ELN-4128-2022; EXZ-0745-2022
    Chemotherapy is controversial in non-metastatic typical carcinoid (TC) tumors. Therefore, it was aimed to evaluate the impact of platin-based chemotherapy on the survival of patients with lung TC. The medical records of patients who underwent surgical resection for non-metastatic TC from 2002 to 2020 at our institution were retrospectively reviewed. Multivariate regression analysis was performed for chemotherapy and prognostic factors in disease-free survival (DFS) in 72 patients. The pathological stages of patients were as follows: 73.6% of the patients were in stage I, 15.3% in stage II and 11.1% in stage III. A total of 5 patients (6.9%) received platin-based chemotherapy and 6 patients (8.3%) had recurrences. The DFS rates at 12, 36 and 60 months were 98.5, 95.1 and 92.5%, respectively. Log-rank testing showed that patients who received chemotherapy and had stage III disease had shorter DFS (P=0.021 for chemotherapy and P<0.001 for stage). However, multivariate analysis revealed that the pathological stage was the only statistically significant factor affecting DFS (P=0.016). Platin-based chemotherapy did not improve DFS, and the eighth edition of TNM (tumor, nodes, metastases) staging did have prognostic value for patients with non-metastatic TC. Although resection has satisfying long-term outcomes, studies on new agents are needed to decrease the recurrence rate, particularly in patients with stage III disease.
  • No Thumbnail Available
    Publication
    The evaluation of risk factors leading to early deaths in patients with acute promyelocytic leukemia: A retrospective study
    (Springer, 2022-02-21) Baysal, Mehmet; Gürsoy, Vildan; Hunutlu, Fazıl Çağrı; Erkan, Buket; Demirci, Ufuk; Baş, Volkan; Gülsaran, Sedanur Karaman; Pınar, İbrahim Ethem; Ersal, Tuba; Kırkızlar, Tuğcan Alp; Atlı, Emine Ikbal; Kırkızlar, Hakkı Onur; Ümit, Elif G.; Gürkan, Hakan; Özkocaman, Vildan; Özkalemkaş, Fahir; Demir, Ahmet Muzaffer; Ali, Rıdvan; GÜRSOY, VİLDAN; HUNUTLU, FAZIL ÇAĞRI; ERKAN ÖZMARASALI, BUKET; PINAR, İBRAHİM ETHEM; ERSAL, TUBA; ÖZKOCAMAN, VİLDAN; ÖZKALEMKAŞ, FAHİR; ALİ, RIDVAN; Tıp Fakültesi; İç Hastalıkları Ana Bilim Dalı; Hematoloji Bilim Dalı; 0000-0001-9907-1498 ; 0000-0002-4991-9830 ; CTT-7336-2022; KCK-7512-2024; CPN-8681-2022; JGM-6601-2023; AAJ-4354-2021; JIR-6730-2023; DLR-8474-2022; GXD-8209-2022
    Acute promyelocytic leukemia (APL) differs from other forms of acute myeloid leukemia (AML), including coagulopathy, hemorrhage, disseminated intravascular coagulation (DIC), and treatment success with all-trans retinoic acid (ATRA). Despite ATRA, early deaths (ED) are still common in APL. Here, we evaluated factors associated with ED and applicability of scoring systems used to diagnose DIC. Ninety-one APL patients (55 females, 36 males, and median age 40 years) were included. ED was defined as deaths attributable to any cause between day of diagnosis and following 30th day. DIC was assessed based on DIC scoring system released by the International Society of Thrombosis and Hemostasis (ISTH) and Chinese Diagnostic Scoring System (CDSS). Patients' median follow-up time was 49.2 months, and ED developed in 14 (15.4% of) cases. Patients succumbing to ED had higher levels of the Eastern Cooperative Oncology Group Performance Status (ECOG PS), lactate dehydrogenase (LDH), and ISTH DIC, and lower fibrinogen levels (p <0.05). In multivariate Cox regression analysis, age >55 and ECOG PS >= 2 rates were revealed to be associated with ED. Based on ISTH and CDSS scores, DIC was reported in 47.3 and 58.2% of the patients, respectively. Despite advances in APL, ED is still a major obstacle. Besides the prompt recognition and correction of coagulopathy, those at high ED risk are recommended to be detected rapidly. Implementation of local treatment plans and creating awareness should be achieved in hematological centers. Common utilization of ATRA and arsenic trioxide (ATO) may be beneficial to overcome ED and coagulopathy in APL patients.